Review
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 28, 2013; 19(44): 7947-7954
Published online Nov 28, 2013. doi: 10.3748/wjg.v19.i44.7947
MicroRNAs as tools to predict glucocorticoid response in inflammatory bowel diseases
Sara De Iudicibus, Marianna Lucafò, Stefano Martelossi, Chiara Pierobon, Alessandro Ventura, Giuliana Decorti
Sara De Iudicibus, Stefano Martelossi, Chiara Pierobon, Institute for Maternal and Child Health IRCCS Burlo Garofolo, 34137 Trieste, Italy
Marianna Lucafò, Alessandro Ventura, Department of Medical, Surgical and Health Sciences, University of Trieste, 34127 Trieste, Italy
Giuliana Decorti, Department of Life Sciences, University of Trieste, 34127 Trieste, Italy
Author contributions: De Iudicibus S, Lucafò M, Martelossi S, Pierobon C, Ventura A and Decorti G contributed equally to the paper.
Supported by Italian Ministry of Health, No. 44/GR-2010-2300447
Correspondence to: Giuliana Decorti, MD, Department of Life Sciences, University of Trieste, via Fleming 22, I-34127 Trieste, Italy. decorti@units.it
Telephone: +39-40-5588777 Fax: +39-40-5582011
Received: August 28, 2013
Revised: October 16, 2013
Accepted: October 19, 2013
Published online: November 28, 2013
Processing time: 104 Days and 22.7 Hours
Core Tip

Core tip: Studies on microRNAs (miRNAs) and pharmacogenomics represent a promising investigation topic that could increase the understanding of the pharmacology of steroids in inflammatory bowel diseases (IBDs) and possibly in other diseases. A number of studies have shown that glucocorticoids (GCs) can modify the expression profiles of different miRNAs, however, the obtained results have been highly variable, and to date it is not possible to recognize a specific miRNA pattern regulated by GCs. Moreover, existing studies employed techniques based on the use of reverse transcription quantitative polymerase chain reaction and microarrays, through the analysis and quantification of already known miRNAs. Using next generation sequencing technologies, it could be possible to detect novel, still unrecognised miRNAs, and identify new miRNA isoforms (iso-miRs) as well. This innovative approach could be a valuable tool for a better understanding of the role of miRNAs to predict steroid response in IBDs. In the future, the increased availability and the reduced costs of RNA profiling should enable the clinicians to stratify patients on specific miRNA biomarkers before starting GC treatment.